Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Show More...
-
Website https://www.aclaristx.com
-
Sector Healthcare
-
Industry Diagnostics & Research
-
Last Quote 1.46 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.65 -0.99 -3.79 -2.25 -2.44 -4.03 -3.9 -3.36 Dividends USD Payout Ratio % * Shares Mil 11.0 11.0 6.0 21.0 28.0 33.0 41.0 41.0 Book Value Per Share * USD -1.89 3.11 7.92 3.55 2.06 1.39 Free Cash Flow Per Share * USD -1.01 -1.45 -1.72 -3.03 -2.58 Return on Assets % -49.1 -53.93 -41.5 -35.59 -32.66 -51.14 -86.32 -79.64 Financial Leverage (Average) 1.02 1.04 1.08 1.28 1.4 1.66 Return on Equity % -64.46 -36.7 -34.72 -60.28 -113.22 -115.94 Return on Invested Capital % -64.75 -36.7 -34.69 -52.99 -112.73 -98.7 Interest Coverage Current Ratio 36.47 11.26 55.64 22.27 15.69 6.57 3.74 4.01 Quick Ratio 36.31 11.12 54.58 22.05 15.23 6.32 3.38 3.88 Debt/Equity 0.14 0.18